白血病
CD40
免疫学
免疫系统
髓系白血病
癌症研究
细胞毒性
髓样
生物
白细胞介素12
细胞毒性T细胞
生物化学
体外
作者
Régis Costello,Françoise Mallet,Hérvè Chambost,Danielle Sainty,Christine Arnoulet,J. A. Gastaut,Christophe Caux
出处
期刊:Leukemia
[Springer Nature]
日期:2000-01-01
卷期号:14 (1): 123-128
被引量:11
标识
DOI:10.1038/sj.leu.2401628
摘要
The CD40 antigen is a member of the tumor necrosis factor receptor superfamily which interacts with its ligand and regulates the immune response via a dialogue between T-lymphocytes and antigen-presenting or tumor cells. Tumor triggering via CD40 exerts direct effects on cancer cells, which have mainly been investigated in terminally differentiated hematological malignancies such as low-grade lymphoma. We focused our attention on minimally differentiated acute myeloid leukemia (AML-M0), an aggressive hematological malignancy in which severe prognosis suggests the requirement for innovative therapeutic strategies. Here we demonstrate, for the first time to our knowledge, a CD40-triggered IL-8, RANTES and IL-12 secretion by leukemic cells. Supernatants from CD40-stimulated leukemia cells had chemoattractant effects on T-lymphocytes, natural killer cells and monocytes. Moreover, these supernatants, when complemented with low-dose IL-2, induced significant lymphokine-activated and natural killer cytotoxicity, leading to leukemia lysis both in allogenic HLA-matched and autologous settings. Stimulation of leukemia cells via CD40 could participate significantly to the anti-leukemia immune response by contributing to the development of an inflammatory response and to in situ cytotoxicity. Leukemia(2000) 14, 123-128.
科研通智能强力驱动
Strongly Powered by AbleSci AI